• Metastatic colorectal cancer:
    • In combination with fluorouracil-based chemotherapy:
      • Bolus-IFL (ie, irinotecan, 5-FU, leucovorin): IV 5mg/kg/dose every 2 weeks
      • FOLFOX4 (ie, oxaliplatin, 5-FU, leucovorin): IV 10mg/kg/dose every 2 weeks
    • In combination with a fluoropyrimidine (eg, 5-FU, capecitabine) plus irinotecan or oxaliplatin-based chemotherapy: IV 5mg/kg every 2 weeks OR  IV 7.5mg/kg every 3 weeks 
  • First-line in non-squamous non-small cell lung cancer:
    • IV 15mg/kg/dose every 3 weeks
    • Use in combination with carboplatin and paclitaxel
    • For patients with unresectable, locally advanced, recurrent or metastatic disease 
  • Renal cell carcinoma:
    • IV 10mg/kg every 2 weeks
    • Used in combination with interferon alfa-2a
  • Cervical cancer:
    • IV 15mg/kg every 3 weeks
    • Used in combination with regimens: paclitaxel and cisplatin or paclitaxel and topotecan
    • For persistent, recurrent or metastatic cervical cancer 
  • Recurrent glioblastoma multiforme:
    • IV 10mg/kg every 2 weeks 
  • Ovarian, fallopian tube or peritoneal cancer:
    • Platinum-resistant:
      • IV 10mg/kg every 2 weeks in combination with IV chemotherapy regimens of: paclitaxel, pegylated liposomal doxorubicin or topotecan weekly OR IV 15mg/kg IV every 3 weeks in combination with topotecan every 3 weeks
      • Patients who have received no more than 2 prior chemotherapy regimens 
    • Platinum-sensitive:
      • IV 15mg/kg every 3 weeks in combination with carboplatin and paclitaxel for 6-8 cycles OR IV 15mg/kg every 3 weeks in combination with carboplatin and gemcitabine for 6-10 cycles then IV 15mg/kg every 3 weeks as a single agent until disease progression 
  • Treatment of stage III or IV disease following initial surgical resection:
    • IV 15mg/kg every 3 weeks in combination with carboplatin and paclitaxel for up to 6 cycles followed by IV 15mg/kg every 3 weeks as a single agent for a total of up to 22 cycles or until disease progression, whichever occurs earlier 
  • First-line unresectable or metastatic hepatocellular carcinoma:
    • IV 15 mg/kg on Day 1 (after administration of atezolizumab), PLUS atezolizumab IV 1,200mg/kg on Day 1
    • Repeat every 3 weeks
    • Continue until disease progression or unacceptable toxicity
  • Neovascular age-related macular degeneration (Off-label):
    • 25mg intravitreally every month
    • May decrease to 1.25mg intravitreally PRN after 3 doses

Injection:

  • 100 mg/4mL
  • 400mg/16mL
  • Withhold for at least 28 days before elective surgery
  • Do not administer until at least 28 days after a major surgery and until adequate wound healing

VEGF inhibitor anticancer

It binds and inhibits vascular endothelial growth factor (VEGF), resulting in decreased angiogenesis, tumor growth and cancer progression

  • Fatigue
  • Diarrhea
  • Nausea
  • Hypertension
  • Epistaxis
  • Headache
  • Arthralgia
  • Dyspnea
  • Stomatitis
  • Pain
  • Anorexia
  • Dysphonia
  • Proteinuria
  • Muscular weakness
  • Neutropenia
  • Weight loss
  • Cough
  • Myalgia
  • Hyperglycemia
  • Back pain
  • Thrombocytopenia
  • Hypomagnesemia
  • Abdominal pain
  • Vomiting
  • Rhinitis
  • Dizziness
  • Hyponatremia
  • Increased creatine
  • Exfoliative dermatitis
  • Hypoalbuminemia
  • Thromboembolism
  • Mucositis
  • Sinusitis
  • Dysgeusia
  • Xeroderma
  • Rectal hemorrhage
  • Lacrimation disorder
  • Nasal septal perforation
  • Hypersensitivity to components
  • Breastfeeding during treatment and for 6 months after discontinuation (oncologic use)
  • Ovarian cancer with recto-sigmoid or bowel involvement
  • Uncontrolled hypertension
  • Severe hemorrhage
  • Recent hemoptysis
  • GI perforation
  • Fistula
  • Unhealed surgical wound
  • Major surgery with in prior 28 days
  • Avoid treatment for at least 28 days before elective surgery
  • Cidofovir

                          Drug Status

Availability Prescription only
Pregnancy Category C
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Avastin 100mg/4mL Injection 1’s F. Hoffman-La Roche Roche Kenya
Avastin 400mg/16mL Injection 1’s F. Hoffman-La Roche Roche Kenya
Bevaas 100mg/4mL Injection 1’s Hetero Biopharma Unisel Ltd
Bevaas 400mg/16mL Injection 1’s Hetero Biopharma Unisel Ltd
Bevacizumab Amring 400mg/16mL Injection 1’s Amring Pharma Prodigy Healthcare
Bevacizumab Amring 100mg/4mL Injection 1’s Amring Pharma Prodigy Healthcare